論文

査読有り
2012年2月

Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: A retrospective study

INTERNATIONAL JOURNAL OF UROLOGY
  • Shintaro Maru
  • ,
  • Takashige Abe
  • ,
  • Nobuo Shinohara
  • ,
  • Ataru Sazawa
  • ,
  • Satoru Maruyama
  • ,
  • Toru Harabayashi
  • ,
  • Shin Suzuki
  • ,
  • Katsuya Nonomura

19
2
開始ページ
110
終了ページ
116
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/j.1442-2042.2011.02913.x
出版者・発行元
WILEY-BLACKWELL

Objectives: To investigate the influence of baseline renal function and dose reduction of chemotherapeutic agents on the outcome of metastatic urothelial carcinoma patients with renal impairment.
Methods: A total of 57 patients with metastatic urothelial carcinoma treated by systemic chemotherapy were included in the present study. The 24 h-creatinine clearance was measured before each cycle and dose reduction was carried out according to our guidelines. Patients were divided into two groups according to baseline 24 h-creatinine clearance: fit group (60 mL/min/1.48 m(2)<=) and unfit group (60 mL/min/1.48 m(2)>). Clinical characteristics and final outcomes were compared between the two groups.
Results: There was no significant difference in the total number of chemotherapy cycles of each patient between the two groups (fit group: median 5; unfit group: median 4; P = 0.7466), although dose reduction was carried out significantly more often in the unfit group than in the fit group during treatment (fit group: median 0 cycles; unfit group: median 3.5 cycles; P = 0.0016). Overall, the median survival was 16 months. There was a significant survival difference between the two groups (fit group: median 17 months; unfit group: median 10 months; P = 0.0419). On multivariate analyses, impaired renal function at the baseline remained an adverse factor (HR 2.27, P = 0.01).
Conclusions: "Unfit" was a poor prognostic factor for metastatic urothelial carcinoma. The dose reduction strategy contributed to continuous treatment in the unfit group. However, its contribution to the prognosis of unfit patients is uncertain.

Web of Science ® 被引用回数 : 16

リンク情報
DOI
https://doi.org/10.1111/j.1442-2042.2011.02913.x
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/22126100
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000299417900005&DestApp=WOS_CPL

エクスポート
BibTeX RIS